On May 11, 2026, Rani Therapeutics Holdings, Inc. was notified by Nasdaq that its stock no longer meets the minimum bid price requirement of $1.00 per share, beginning a 180-day period to rectify this issue or face potential delisting. Additionally, the CFO Svai Sanford will resign after appointing a successor, receiving $491,400 for nine months post-departure along with benefits and accelerated vesting of stock options.